Staff and Wire Reports
Wednesday, 04 April 2012 04:42
Trading on the Euronext, Pharming Group NV (NYSE Euronext: PHARM) produces, purifies and formulates recombinant human proteins using its transgenic technology platform for therapeutic indications in Hereditary Angioedema, Transplant Rejection, Blood Coagulation Disorders and Ischemic Reperfusion Injury.
Pharming Group develops products for various applications in humans. Its product areas include: biopharmaceuticals, biomaterials and bionutritionals. Its product portfolio includes its Rhucinr, a recombinant human C1 esterase inhibitor, is being developed as a replacement therapy for patients who suffer from hereditary angioedema (HAE). Late last month, the company announced that it has entered into an agreement with Hyupjin Corporation, to commercialize RUCONEST for the treatment of acute attacks of Hereditary Angioedema (HAE) in the Republic of Korea.
The firm’s innovative therapeutics for the treatment of genetic disorders and ageing diseases, as well as specialty products for surgical indications, and intermediates for nutritional products and a variety of other applications are preparing to enter humans after some impressive results in pre-clinical studies. Despite being early in their development pipeline, they have several partnerships and collaborations with Swedish Orphan Biovitrum AB, GTC Biotherapeutics Inc, AgResearch, Eczacibasi Ilac, Pazarlama, Esteve, NovaThera, Schering-Plough, Aslan, and even the US Army.
Sijmen de Vries, the Chief Executive Officer of the company recently sat down with BioMedReports to discuss the frim's truly innovative technology platform which involves a recombinant human C1 esterase inhibitor obtained from the milk of transgenic rabbits.
Dr de Vries, MD MBA, is responsible for the overall management of the company- which is still early in their development process. Dr de Vries has extensive senior level experience in both the pharmaceutical and biotechnology industries. He joins Pharming from Swiss-based 4-Antibody where he was CEO. Dr de Vries has also been CEO of Morphochem and prior to this spent many years at Novartis and at SmithKline Beecham Pharmaceuticals where he held senior business and commercial positions. Dr de Vries also holds non-executive directorships in two private life science companies. Dr de Vries holds a Medical Degree from the University of Amsterdam and a MBA in General Management from Ashridge Management College (UK).
His exclusive interview can be seen below:
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites